ArticleGut2014
Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire.
Article in Gut, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 99 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis
Comparison of Patient Reported Disease Activity Scores Combined With Fecal Calprotectin Home Tests for Remote Monitoring of IBD Patients: a Multicenter Prospective Validation Study
Who cites it
99 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Patient-reported outcome measures poorly correlate with objective inflammatory bowel disease activity measures: a systematic review.Journal of Crohn's & colitis · 2025Pooled it
- Pooled it
- Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?Journal of Crohn's & colitis · 2020Pooled it
- 2'-Fucosyllactose modulates gut microbiota and systemic metabolism in mild-to-moderate ulcerative colitis: a randomized crossover trial.Journal of Crohn's & colitis · 2026Trial
- The relationships between depression, inflammation and self-reported disease activity in IBD and their impact on healthcare usage.BMC gastroenterology · 2025Trial
- A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS).International journal of clinical pharmacy · 2024Trial
- A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn's Disease.Stem cell research & therapy · 2024Trial
- Improving Food-Related Quality of Life in Inflammatory Bowel Disease through a Novel Web Resource: A Feasibility Randomised Controlled Trial.Nutrients · 2022Trial
- Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial.Medicine · 2017Trial
- Validation of a Patient-Created, Patient-Reported Experience Measure for Inflammatory Bowel Disease in the United Kingdom.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Advancing Predictive Modeling of Inflammatory Bowel Disease (IBD) Flares: A Data-Driven Approach Using Lifestyle and Psychosocial Factors from a Remote Monitoring Platform.Digestive diseases and sciences · 2026Observational
- A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost-Effective: Results of the Multicentre IBD Value Study.Alimentary pharmacology & therapeutics · 2026Article
- Beyond the Average: Modeling Individual-Specific Preferences for Ulcerative Colitis Surgery.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026Article
- Fatigue and mood disorders are highly prevalent in patients with inflammatory bowel disease: a single-centre, cross-sectional study using patient-reported outcomes.Internal medicine journal · 2026Article
- Prevalence of Fatigue Among Inflammatory Bowel Disease Patients at a Tertiary Center in Saudi Arabia.Journal of clinical medicine · 2026Article
- Evaluation of the Validity and Reliability of the Persian Version of IBDcQ-8 Questionnaire.Archives of Iranian medicine · 2026Article
- Article
- Medical Gaslighting in Gastroenterology: A Narrative Review From Pediatric and Adult Practice.Gastro hep advances · 2026Review
- The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes.Therapeutic advances in gastroenterology · 2026Article
- Health-Related Physical Fitness in Patients With Inflammatory Bowel Disease vs Healthy Control Subjects.Inflammatory bowel diseases · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe use of patient reported outcome measures to support routine inflammatory bowel disease (IBD) care is not widespread and suggests that existing questionnaires lack relevance to day-to-day decisions or are too cumbersome to administer. We developed a simple, generic tool for capturing disease control from the patient's perspective to address these barriers.
methodsDevelopment based on literature review, patient focus groups/interviews and a steering group, defining a limited set of generic questions. The 'IBD-Control' questionnaire comprises 13 items plus a visual analogue scale (VAS) (0-100). Prospective validation involved baseline completion of IBD-Control, quality of life (QoL) questionnaire (UK-IBD-Q), EuroQol (EQ-5D), Hospital Anxiety and Depression Score; and clinician assessment (blinded to questionnaire; recording Harvey-Bradshaw Index or Simple Clinical Colitis Activity Index; Global Clinician Rating; treatment outcome).
results299 patients returned baseline surveys (Crohn's disease, n=160; ulcerative colitis, n=139) and 138 attended for repeat visits. Completion time (mean; SD): 1 min 15 s; 25 s; Internal consistency: Cronbach's α for all 13 items (0.85); for subgroup of eight questions ('IBD-Control-8'; 0.86). Strong correlation between IBD-Control-8 and IBD-Control-VAS (r=0.81). Test-retest reliability (2 week repeat): intra-class correlation=0.97 for IBD-Control-8 and 0.96 for IBD-Control-VAS. Construct validity: Moderate-to-strong correlations between IBD-Control-8 and IBD-Control-VAS versus activity indices, UK-IBD-Q and EQ-5D (utility) with r values 0.52-0.86. Discriminant validity (mean instrument scores for remission, mild, moderate or severe): p<0.001 (analysis of variance (ANOVA)). Sensitivity to change: Effect sizes: 0.76-1.44.
conclusionsThe IBD-Control is a rapid, reliable, valid and sensitive instrument for measuring overall disease control from the patient's perspective. Unlike existing patient reported outcome measures, its simplicity, ease-of-use and generic applicability make it a candidate for supporting routine care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.